Konski Quoted on Myriad Patent Case

10 October 2014 Bloomberg BNA’s Patent, Trademark & Copyright Journal News

Bloomberg BNA’s Patent, Trademark & Copyright Journal

Partner Antionette Konski was quoted in a Bloomberg BNA’s Patent, Trademark & Copyright Journal article, “Myriad Likely Heading Back to Trial Without Injunction Against DNA Screening Competitor,” on October 10, 2014. The article analyzes the Myriad Genetics Inc. case surrounding the eligibility of its patents related to genes linked to breast cancer. Konski was quoted saying, “I think [Myriad’s attorney] succeeded in making the point that one can use old or conventional technology to create something new and patentable.”

When asked to weigh in on the appeals court’s decision, Konski said, “The Federal Circuit will likely affirm denial of the preliminary injunction and return the case to the district court with instructions how to apply Alice/AMP/Mayo and allow the court to further develop the record to correctly apply the facts.”

Related Services

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Cloud security inadequate for Cyber threats, are you surprised?
19 July 2019
Internet, IT & e-Discovery Blog
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ